Eric M. Dube
Chief Executive Officer at Travere Therapeutics Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Travere Therapeutics Inc., 3 years.
Travere Therapeutics Inc.
Director · CHIEF EXECUTIVE OFFICER
OnKure Therapeutics Inc.
Director
Chief executive roles
Travere Therapeutics Inc.
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 9, 2024 | Travere Therapeutics Inc. | Open-market sale | −21,125 | $11.52 | $243,360 |
| Sep 5, 2024 | Travere Therapeutics Inc. | Grant or award | +32,500 | — | — |
| Feb 1, 2024 | Travere Therapeutics Inc. | Open-market sale | −9,106 | $8.53 | $77,674 |
| Feb 1, 2024 | Travere Therapeutics Inc. | Open-market sale | −10,016 | $8.86 | $88,742 |
| Jan 31, 2024 | Travere Therapeutics Inc. | Grant or award | +135,000 | — | — |
| Jan 23, 2024 | Travere Therapeutics Inc. | Open-market sale | −7,873 | $8.96 | $70,542 |
| Sep 5, 2023 | Travere Therapeutics Inc. | Open-market sale | −4,455 | $14.71 | $65,533 |
| Aug 31, 2023 | Travere Therapeutics Inc. | Grant or award | +9,900 | — | — |
| Feb 1, 2023 | Travere Therapeutics Inc. | Open-market sale | −8,196 | $22.25 | $182,361 |
| Jan 31, 2023 | Travere Therapeutics Inc. | Grant or award | +97,500 | — | — |
| Jan 24, 2023 | Travere Therapeutics Inc. | Open-market sale | −6,442 | $21.50 | $138,503 |
| Jan 5, 2023 | Travere Therapeutics Inc. | Open-market sale | −5,625 | $20.75 | $116,719 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.